Ziritaxestat 5 mg | 99.67%
TargetMol
Ziritaxestat (GLPG1690), an autotaxin inhibitor, currently being evaluated in an exploratory phase 2 study in idiopathic pulmonary fibrosis patients.
More Information Supplier PageZiritaxestat
Search Results
Lapatinib 100 mg | 99.89%
TargetMol
Lapatinib is a dual inhibitor of Lapatinib is a dual ErbB2/EGFR (IC50: 9.2/10.8 nM) inhibitor
More Information Supplier PageLapatinib
SU 4313 25 mg | 99.89%
TargetMol
SU 4313
SU 4313 2 mg | 99.89%
TargetMol
SU 4313
SU 4313 5 mg | 99.89%
TargetMol
SU 4313
SU 4313 50 mg | 99.89%
TargetMol
SU 4313
SU 4313 10 mg | 99.89%
TargetMol
SU 4313
SU 4313 100 mg | 99.89%
TargetMol
SU 4313
Lapatinib 200 mg | 99.89%
TargetMol
Lapatinib is a dual inhibitor of Lapatinib is a dual ErbB2/EGFR (IC50: 9.2/10.8 nM) inhibitor
More Information Supplier PageLapatinib
Silmitasertib 100 mg | 99.47%
TargetMol
CX-4945 is a potent, orally bioavailable inhibitor of casein kinase 2 (CK2; Ki: 0.38 nM).
More Information Supplier PageSilmitasertib
